Archives
-
Ionomycin Free Acid for FAK–Calpain 2 Assays
2026-09-23
Ionomycin free acid enables controlled calcium ion transport for testing how intracellular calcium may influence FAK stability, Calpain 2-dependent proteolysis, adhesion, and migration. This workflow-focused guide translates the FAISL–FAK findings into practical calcium perturbation experiments while distinguishing established evidence from testable assay hypotheses.
-
AZD0156: Precision ATM Kinase Inhibitor Workflows
2026-09-22
AZD0156 enables controlled interrogation of ATM-dependent DNA repair, checkpoint signaling, and metabolic adaptation in cancer models. This workflow-focused guide translates evidence on macropinocytosis and branched-chain amino acid uptake into practical assay designs, controls, and troubleshooting strategies.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-09-22
The reference study develops a localized, nonviral tumor-suppressor replacement strategy in which chemically modified p21 mRNA is encapsulated in lipid nanoparticles and administered intravesically. In an orthotopic mouse model, this approach restored p21 expression, altered cell-cycle and DNA-damage pathways, and suppressed bladder tumor growth while limiting systemic distribution.
-
Selonsertib (GS-4997) for Stress-Pathway Assays
2026-09-21
Selonsertib (GS-4997) enables selective ASK1 pathway interrogation in oxidative stress, inflammation, fibrosis, and metabolic disease models. This article develops an assay-design framework connecting ASK1 signaling with the Galectin-1–FIP200 autophagy axis without overstating evidence from hepatic steatosis studies.
-
8-DY547-cGMP for CA2 Signaling Assays
2026-09-21
8-DY547-cGMP offers a fluorescence-based route for investigating cyclic GMP biology alongside hippocampal perineuronal-net studies. This article explains how to use the reagent as an orthogonal assay tool without confusing cGMP measurements with direct evidence of Alzheimer’s disease pathology.
-
Vorinostat: HDAC Inhibition in Cancer Research
2026-09-20
Vorinostat, also called suberoylanilide hydroxamic acid, is an HDAC inhibitor that increases histone acetylation and changes transcriptional programs. Its research value spans epigenetic modulation in oncology, apoptosis assays, and cutaneous T-cell lymphoma models, but biochemical potency and cell-growth IC50 values are assay-dependent.
-
NMDA: From Excitotoxicity to Ferroptosis Assays
2026-09-19
Explore how NMDA (N-Methyl-D-aspartic acid) connects receptor-driven excitotoxicity with oxidative stress and ferroptosis measurements. This article translates a retinal ganglion cell study into practical assay-design guidance for mechanistic neuroscience research.
-
Dyngo-4a: A Practical Dynamin Inhibitor Guide
2026-09-18
Dyngo-4a is a research-grade dynamin inhibitor for testing vesicle scission, clathrin-dependent uptake, and cargo trafficking. This guide translates its mechanism into practical dose-response, imaging, neuronal, and lipid nanoparticle mRNA assay workflows while separating established evidence from experimental extensions.
-
Moxidectin Potentiates Polyenes Against Oral Candidiasis
2026-09-18
A 2024 study found that Moxidectin enhances amphotericin B and nystatin activity against Candida albicans by increasing fungal ergosterol biosynthesis and polyene binding. The combination reduced fungal burden and tongue inflammation in a mouse oral candidiasis model, supporting moxidectin as an experimental polyene potentiator rather than an established antifungal therapy.
-
TAI-1: Hec1 Inhibition from Cell Origin to Assay
2026-09-17
TAI-1 is a potent Hec1 inhibitor whose mitotic mechanism can be studied more rigorously when cell state, RB1 biology, and assay design are considered together. This article connects TAI-1 pharmacology with new retinal organoid evidence while defining practical boundaries for cancer research interpretation.
-
Antiseptics for Burns: Evidence, Methods, and Gaps
2026-09-17
The 2017 Cochrane review of antiseptics for burns examined whether topical antiseptic and antibiotic approaches improve healing, prevent infection, or reduce treatment-related harm. Its main contribution was a structured comparison of clinically important outcomes across heterogeneous studies, showing why differences in dressings, patient populations, and outcome definitions limit confident conclusions.
-
Tropifexor (LJN452) for Reliable FXR Assays
2026-09-16
A scenario-based guide to using Tropifexor (LJN452), SKU BA3602, in FXR, viability, proliferation, and intestinal barrier experiments. It explains concentration planning, DMSO controls, interpretation limits, and practical criteria for selecting a research-grade small molecule.
-
NMDA for Excitotoxicity and RGC Research
2026-09-16
Use NMDA to create a controlled receptor-mediated injury stimulus for excitotoxicity research, calcium influx measurement, and oxidative stress assay development. A workflow built around fresh dosing, temporal sampling, and BMP4-GPX4 pathway readouts can connect neuronal injury phenotypes with retinal stem-cell and glaucoma model questions.
-
Intestinal Stretch, Obesity, and Weight-Loss Recovery
2026-09-15
This study shows that intestinal stretch acutely suppresses feeding and improves oral glucose tolerance through mechanisms that do not require classical GLP-1 signaling. Obesity weakens this gut–brain response, whereas dietary and surgical weight loss restore intestinal stretch-induced satiety and enhance neuronal activation in the nucleus of the solitary tract.
-
Mutant p53-R280K Rewires FASN-Driven Lipogenesis
2026-09-15
A 2026 Molecular Biology Reports study identifies a gain-of-function mechanism in which mutant p53-R280K co-opts SREBP1 to activate FASN transcription, increase de novo fatty acid synthesis, and promote breast cancer progression. The work connects a specific TP53 mutation to lipid metabolic reprogramming and shows that both genetic and pharmacological FASN inhibition can suppress the resulting malignant phenotypes.